EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSUAMG00000027627
Gene Symbol: NR1H4
2 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSUAMG00000022894
Gene Symbol: NR3C1
2 Cross references
278 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSUAMG00000009899
Gene Symbol: OPRD1
2 Cross references
252 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSUAMG00000004254
Gene Symbol: OPRM1
2 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSUAMG00000002170
Gene Symbol: OPRL1
2 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSUAMG00000024185
Gene Symbol: OXTR
2 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSUAMG00000002520
Gene Symbol: PAK4
2 Cross references
163 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSUAMG00000012501
Gene Symbol: PNLIP
2 Cross references
300 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSUAMG00000025561
Gene Symbol: PTH1R
2 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSUAMG00000008877
Gene Symbol: PPARA
2 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSUAMG00000014221
Gene Symbol: PPARD
2 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSUAMG00000002110
Gene Symbol: PPARG
2 Cross references
405 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).